Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Boehringer Ingelheim

Status: Completed

Conditions: Heart Failure

Treatments: Drug: JARDIANCE®

Study type: Observational

Funder types: Industry

Identifiers

NCT05262764

1245-0286

Details and patient eligibility

About

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.

Enrollment: 1,200 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
• Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment

Exclusion criteria

• None

Trial design

1,200 participants in 1 patient group

JARDIANCE®

Description:

Patients in Japan with chronic heart failure who were prescribed JARDIANCE® tablets and who were never treated with Empagliflozin before enrolment. Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS). Patients were observed for up to 52 weeks after start of the treatment or until discontinuation of administration.

Treatment:

Drug: JARDIANCE®